. 2012 Oct 8;75(5):1289–1298. doi: 10.1111/j.1365-2125.2012.04477.x

Table 2.

Summary of all adverse events that occurred in two or more CNTO 5825-treated subjects

	Pooled placebo subjects	Cohort 1, 0.1 mg kg⁻¹ i.v.	Cohort 2, 0.3 mg kg⁻¹ i.v.	Cohort 3, 1.0 mg kg⁻¹ i.v.	Cohort 4, 3.0 mg kg⁻¹ i.v.	Cohort 5, 10 mg kg⁻¹ i.v.	Cohort 6, 3.0 mg kg⁻¹ s.c.	Cohort 7, atopic subjects, 10 mg kg⁻¹ i.v.	Combined
Subjects treated (n)	16	6	6	6	6	6	6	12	48
Total number of subjects with adverse events [n (%)]	9 (56.3)	5 (83.3)	2 (33.3)	6 (100.0)	4 (66.7)	5 (83.3)	0 (0.0)	10 (83.3)	32 (66.7)
Headache	2 (12.5)	3 (50.0)	0 (0.0)	1 (16.7)	1 (16.7)	1 (16.7)	0 (0.0)	2 (16.7)	8 (16.7)
Nasopharyngitis	0 (0.0)	3 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	2 (16.7)	6 (12.5)
Back pain	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	3 (6.3)
Diarrhoea	1 (6.3)	0 (0.0)	1 (16.7)	0 (0.0)	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	3 (6.3)
Oropharyngeal pain	1 (6.3)	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	3 (6.3)
Dizziness	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	2 (4.2)
Vomiting	0 (0.0)	0 (0.0)	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.2)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	1 (8.3)	2 (4.2)
Influenza-like illness	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.2)
Erythema	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.2)
Palpitations	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.2)
Hypersensitivity	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (16.7)	2 (4.2)
Limb injury	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	2 (4.2)
Myalgia	1 (6.3)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	2 (4.2)